Early increase of CA 19-9 in advanced pancreatic cancer receiving FOLFIRINOX: Is it a sign of efficacy?
LMJ-Lebanese Medical Journal. 2016; 64 (2): 97-99
in English
| IMEMR
| ID: emr-191216
ABSTRACT
Advanced pancreatic cancer [APC], one of the most aggressive tumors, was considered to be resistant to chemotherapy for decades. FOLFIRINOX [5-FU, leucovorin, irinotecan and oxaliplatin] regimen showed an improvement of quality of life and overall survival in APC patients with good performance status [ECOG < 2]
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Lebanese Med. J.
Year:
2016
Similar
MEDLINE
...
LILACS
LIS